These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 38234020)

  • 21. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G; Loupakis F; Salvatore L; Fornaro L; Cremolini C; Cupini S; Ciarlo A; Del Monte F; Cortesi E; Amoroso D; Granetto C; Fontanini G; Sensi E; Lupi C; Andreuccetti M; Falcone A
    Lancet Oncol; 2010 Sep; 11(9):845-52. PubMed ID: 20702138
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I study of vincristine, irinotecan, temozolomide and bevacizumab (vitb) in pediatric patients with relapsed solid tumors.
    Venkatramani R; Malogolowkin M; Davidson TB; May W; Sposto R; Mascarenhas L
    PLoS One; 2013; 8(7):e68416. PubMed ID: 23894304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan.
    Packer RJ; Jakacki R; Horn M; Rood B; Vezina G; MacDonald T; Fisher MJ; Cohen B
    Pediatr Blood Cancer; 2009 Jul; 52(7):791-5. PubMed ID: 19165892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety.
    Kang TY; Jin T; Elinzano H; Peereboom D
    J Neurooncol; 2008 Aug; 89(1):113-8. PubMed ID: 18438609
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic therapy for high-grade glioma.
    Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
    Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab-containing regimen in relapsed/progressed brain tumors: a single-institution experience.
    Schiavetti A; Varrasso G; Mollace MG; Dominici C; Ferrara E; Papoff P; Di Biasi C
    Childs Nerv Syst; 2019 Jun; 35(6):1007-1012. PubMed ID: 30903281
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.
    Desjardins A; Reardon DA; Herndon JE; Marcello J; Quinn JA; Rich JN; Sathornsumetee S; Gururangan S; Sampson J; Bailey L; Bigner DD; Friedman AH; Friedman HS; Vredenburgh JJ
    Clin Cancer Res; 2008 Nov; 14(21):7068-73. PubMed ID: 18981004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A phase II trial with bevacizumab and irinotecan for patients with primary brain tumors and progression after standard therapy.
    Møller S; Grunnet K; Hansen S; Schultz H; Holmberg M; Sorensen M; Poulsen HS; Lassen U
    Acta Oncol; 2012 Jul; 51(6):797-804. PubMed ID: 22548369
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A pediatric trial of radiation/cetuximab followed by irinotecan/cetuximab in newly diagnosed diffuse pontine gliomas and high-grade astrocytomas: A Pediatric Oncology Experimental Therapeutics Investigators' Consortium study.
    Macy ME; Kieran MW; Chi SN; Cohen KJ; MacDonald TJ; Smith AA; Etzl MM; Kuei MC; Donson AM; Gore L; DiRenzo J; Trippett TM; Ostrovnaya I; Narendran A; Foreman NK; Dunkel IJ
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544128
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-angiogenic therapy for high-grade glioma.
    Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
    Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab plus irinotecan in recurrent or progressive malign glioma: a multicenter study of the Anatolian Society of Medical Oncology (ASMO).
    Demirci U; Tufan G; Aktas B; Balakan O; Alacacioglu A; Dane F; Engin H; Kaplan MA; Gunaydin Y; Ozdemir NY; Tugba Unek I; Karaca H; Akman T; Sonmez OU; Coskun U; Harputluoglu H; Sevinc A; Tonyali O; Buyukberber S; Benekli M
    J Cancer Res Clin Oncol; 2013 May; 139(5):829-35. PubMed ID: 23400732
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I study of panobinostat in combination with bevacizumab for recurrent high-grade glioma.
    Drappatz J; Lee EQ; Hammond S; Grimm SA; Norden AD; Beroukhim R; Gerard M; Schiff D; Chi AS; Batchelor TT; Doherty LM; Ciampa AS; Lafrankie DC; Ruland S; Snodgrass SM; Raizer JJ; Wen PY
    J Neurooncol; 2012 Mar; 107(1):133-8. PubMed ID: 21984064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience.
    Mesti T; Moltara ME; Boc M; Rebersek M; Ocvirk J
    Radiol Oncol; 2015 Mar; 49(1):80-5. PubMed ID: 25810706
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
    Alistar A; Morris BB; Desnoyer R; Klepin HD; Hosseinzadeh K; Clark C; Cameron A; Leyendecker J; D'Agostino R; Topaloglu U; Boteju LW; Boteju AR; Shorr R; Zachar Z; Bingham PM; Ahmed T; Crane S; Shah R; Migliano JJ; Pardee TS; Miller L; Hawkins G; Jin G; Zhang W; Pasche B
    Lancet Oncol; 2017 Jun; 18(6):770-778. PubMed ID: 28495639
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent/refractory central nervous system tumors.
    Metts J; Harrington B; Salman E; Bradfield SM; Flanary J; Mosha M; Amankwah E; Stapleton S
    Childs Nerv Syst; 2022 May; 38(5):919-928. PubMed ID: 35260913
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis.
    Xu T; Chen J; Lu Y; Wolff JE
    BMC Cancer; 2010 Jun; 10():252. PubMed ID: 20525214
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy.
    Reardon DA; Desjardins A; Peters KB; Vredenburgh JJ; Gururangan S; Sampson JH; McLendon RE; Herndon JE; Coan A; Threatt S; Friedman AH; Friedman HS
    Cancer; 2011 Dec; 117(23):5351-8. PubMed ID: 21590689
    [TBL] [Abstract][Full Text] [Related]  

  • 39. S-1 and irinotecan plus bevacizumab as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer: a multicenter phase II study in Japan (KSCC1102).
    Miyamoto Y; Tsuji A; Tanioka H; Maekawa S; Kawanaka H; Kitazono M; Oki E; Emi Y; Murakami H; Ogata Y; Saeki H; Shimokawa M; Natsugoe S; Akagi Y; Baba H; Maehara Y
    Int J Clin Oncol; 2016 Aug; 21(4):705-712. PubMed ID: 26746689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the Eastern Cooperative Oncology Group study E2200.
    Giantonio BJ; Levy DE; O'dwyer PJ; Meropol NJ; Catalano PJ; Benson AB;
    Ann Oncol; 2006 Sep; 17(9):1399-403. PubMed ID: 16873427
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.